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Introduction
Since the first in vitro fertilization (IVF) pregnancy and
birth in 1978, many changes have occurred. Superovu-
lation with clomiphene citrate and subsequent different
gonadotropin preparations is widely used instead of
natural cycles, in order to produce a large number of
oocytes. However, the premature luteinizing hormone
(LH) surge that may occur during ovarian hyper-
stimulation reduces the effectiveness of the regimen and
negatively affects oocyte and embryo quality.
The introduction of a gonadotropin-releasing
hormone agonist (GnRH-a) marked a new era in ova-
rian hyperstimulation, and different regimens have been
developed to achieve an initial increase in gonadotro-
pin secretion (flare-up) or pituitary desensitization. The
GnRH-a long protocol has become the standard method
at most centers.
GnRH-a offers several advantages, but ovarian
stimulation with the GnRH-a long protocol has been
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associated with the need for a higher gonadotropin
dose or even hyporesponsiveness. Recently, it was
proposed that using lower doses of GnRH-a would
provide the same benefit as the standard dose [1].
In this study, we retrospectively summarized and
analyzed our clinical experience of the low-dose GnRH-
a down-regulation protocol in our IVF program and
compared the ovulatory responses and cycle outcomes
with the standard-dose GnRH-a down-regulation pro-
tocol and gonadotropin-alone protocol to evaluate the
advantages and disadvantages of lowering the GnRH-a
dosage.
Materials and Methods
Patient population
All IVF cycles at the Department of Obstetrics and
Gynecology, Taichung Veterans General Hospital, from
January 1, 1996, to December 31, 1998, were reviewed.
Patients who received the GnRH-a long protocol (be-
gun in the mid-luteal phase) and patients who received
the gonadotropin-alone protocol were identified and
included in the analysis.
Protocols and study design
The standard-dose GnRH-a protocol consisted of daily
1 mg leuprolide acetate subcutaneously from the mid-
luteal phase, followed by 0.5 mg daily from the day of
gonadotropin commencement. In the low-dose GnRH-
a protocol, the dosage of leuprolide acetate was 0.5 mg
daily in the luteal phase and further reduced to 0.25 mg
daily on the day of gonadotropin commencement. The
gonadotropin-alone protocol consisted of gonadotropin
only from day 3 of the stimulation cycle.
In all three protocols, 10,000 IU human chorionic
gonadotropin (hCG) was given intramuscularly when
at least two follicles reached a mean diameter of
18 mm or greater. Oocyte retrieval was performed 34 to
35 hours later. The luteal phase was supplemented with
25–50 mg progesterone-in-oil daily until the appear-
ance of embryonic heart motion or proven failure to
conceive. hCG at 5,000 IU was also given on the fifth day
after oocyte retrieval for luteal reinforcement, except
in patients at risk for hyperstimulation syndrome.
Patient characteristics, ovulatory responses, and
pregnancy outcomes were analyzed using the t test and
Chi-squared test, with p less than 0.05 defining a
significant difference.
Results
A total of 181 IVF cycles met our criteria, including 48
cycles with the low-dose GnRH-a protocol (group 1),
37 cycles with the standard-dose GnRH-a protocol
(group 2), and 96 cycles with the gonadotropin-alone
protocol (group 3). There were no significant differences
in terms of age, cause of infertility, or duration of infer-
tility among the three groups (Tables 1 and 2). How-
ever, more patients in group 1 suffered from primary
infertility.
The responses to ovarian stimulation for each
protocol are presented in Table 3. Patients in both
groups 1 and 2 required higher gonadotropin doses
and more days of stimulation than patients in group 3.
Table 1. Characteristics of in vitro fertilization patients at Taichung Veterans General Hospital, 1996–1998
Group 1 (n = 48) Group 2 (n = 37) Group 3 (n = 96)
Age, yr 33.0 ± 4.5 33.1 ± 4.4 32.1 ± 4.1
Duration of infertility, yr 14.9 ± 2.9 15.7 ± 3.7 14.3 ± 2.6
Primary infertility, %    68.8*† 46.0 50.8
Data are expressed as mean ± standard deviation. Group 1 = low-dose GnRH-a protocol; Group 2 = standard-dose GnRH-a protocol; Group 3 = gonadotropin-
alone protocol; n = cycle number. *p < 0.05, group 1 vs group 2; †p < 0.05, group 1 vs group 3.
Table 2. Cause of infertility in in vitro fertilization patients at Taichung Veterans General Hospital, 1996–1998
Group 1 Group 2 Group 3 p
Tubal factor, % 39.02 27.78 47.13 NS
Male factor, % 19.76 18.33 15.75 NS
Unexplained, % 19.51 16.67 11.49 NS
Endometriosis, % 29.27 30.56 22.99 NS
Others, % 12.44 16.66 12.64 NS
Group 1 = low-dose GnRH-a protocol; Group 2 = standard-dose GnRH-a protocol; Group 3 = gonadotropin-alone protocol; NS = no significant difference.
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Preovulatory peak serum estradiol (E2) concentration
and number of retrieved oocytes in group 1 were similar
to groups 2 and 3, but group 1 patients required more
stimulation days and higher total gonadotropin doses.
The pregnancy rates were higher in both long-protocol
groups than the gonadotropin-alone group (36.4% and
29.7% vs 22.9%), but the differences were not significant
(Table 4). There were also no significant differences in
terms of abortion rates and multiple pregnancy rates.
Furthermore, no spontaneous LH surge occurred in
group 1 or 2 patients.
Discussion
The addition of GnRH-a to ovulation induction protocols
has been claimed to play a significant role in improving
assisted reproduction technology (ART) cycle outcomes,
including lower cancellation rates (by suppressing
endogenous LH surges) [2], higher oocyte yields [3,4],
higher pregnancy rates [2], and lower miscarriage rates
in some individuals [5]. We found higher pregnancy
rates and live birth rates in the GnRH-a long protocol
groups than in the gonadotropin-alone group, though
the differences were not significant. However, the
minimal effective dosage is still under investigation.
Sandow et al showed that the doses required to
maintain pituitary suppression decrease with the length
of treatment [6], and Janssens et al showed that as little
as 15–50 µg triptorelin acetate daily is enough for pitui-
tary desensitization [7]. Halving the dosage of leuprolide
acetate depot also provides adequate pituitary desen-
sitization [1]. In this study, no spontaneous LH surge
occurred in the low-dose group, which further con-
vinced us that low-dose GnRH-a can be applied clinically
with confidence.
The rationale for lowering the GnRH-a dosage is to
decrease pituitary suppression and, hence, to obtain
a better ovarian response. Some authors have shown
benefits, with increased numbers of oocytes recovered
or lower total gonadotropin dosages in poor respon-
ders [8–11]. However, in this study, we found that the
low-dose GnRH-a group needed more days of stimu-
lation and a higher total gonadotropin dose, which
is in conflict with our original assumption.
As previously reported, delayed initiation of gona-
dotropin stimulation in the GnRH-a long protocol
(administering a higher total GnRH-a dose before ini-
tiation of gonadotropin) was associated with a signifi-
cant decrease in the subsequent duration of gonadotro-
pin stimulation [12]. If we account for the inverse rela-
tionship between GnRH-a dosage and total gonado-
tropin dose in that report and our data, the GnRH-a
administered for ovarian hyperstimulation may exert
effects not simply through pituitary axis suppres-
sion. Some reports have addressed how GnRH-a can
modulate ovarian steroidogenesis by direct action
[13]; the different effects might depend on the degree
of follicular maturation and/or the type of gonadotro-
pin used [14]. Furthermore, GnRH-a can exert diffe-
rent stimulating and inhibiting effects on ovarian
steroidogenesis in cultured human granulosa cells
due to the absence or presence of gonadotropins in
the culture medium [13]. The modulation effects of
GnRH-a on ovarian hyperstimulation may be more
complex than previously thought. The low dose of
Table 3. Response to stimulation in in vitro fertilization patients at Taichung Veterans General Hospital, 1996–1998
Group 1 Group 2 Group 3
Gonadotropin dosage, Amp  29.3 ± 7.2*† 25.2 ± 7.3‡ 22.0 ± 4.7
Days of stimulation  13.6 ± 2.3*† 11.6 ± 1.9‡ 19.9 ± 1.5
Peak estradiol, pg/mL 2,211 ± 1,284  1,675 ± 1,252 12,253 ± 2,101
Oocyte yields 9.3 ± 4.2  9.6 ± 6.1 19.7 ± 5.8
Data are expressed as mean ± standard deviation. Group 1 = low-dose GnRH-a protocol; Group 2 = standard-dose GnRH-a protocol; Group 3 = gonadotropin-
alone protocol. *p < 0.05, group 1 vs group 2; †p < 0.05, group 1 vs group 3; ‡p < 0.05, group 2 vs group 3.
Table 4. Cycle outcome in in vitro fertilization patients at Taichung Veterans General Hospital, 1996–1998
Group 1 Group 2 Group 3
Embryos transferred/cycle* 5.1 ± 1.9† 4.2 ± 2.0 4.7 ± 2.1
Pregnancy rate, % 36.4 29.7 22.9
Abortion rate, % 25.0 11.1 12.5
Live birth rate, % 27.3 26.4 20.0
Multiple pregnancy rate, % 18.8 22.2 20.8
Group 1 = low-dose GnRH-a protocol; Group 2 = standard-dose GnRH-a protocol; Group 3 = gonadotropin-alone protocol. *Mean ± standard deviation;
†p < 0.05, group 1 vs group 2.
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GnRH-a we used was high enough for complete pitui-
tary desensitization but might possibly diminish the
beneficial direct ovarian effect.
Most trials reducing the GnRH-a dosage were non-
randomized and applied to poor responders [8–10].
Kowalik and colleagues reviewed their database of
patients who underwent at least two cycles of IVF with
different leuprolide dosages, and noted that lowering
the GnRH-a dosage resulted in a faster rise in E2
concentration and a higher peak E2 concentration, but
no difference in oocyte yields [11]. However, in our IVF
program, the low-dose group was associated with sim-
ilar oocyte yields and higher (though not significantly)
peak E2 concentrations, but a higher gonadotropin
dose was needed. This may have been due to the bias
in judging the timing of ovulation induction. However,
if the effects of GnRH-a on the ovary are so complex, may-
be the different ovarian hyperstimulation protocols
and different races (or different mean body weights,
hence, different serum concentrations for the same
GnRH-a dosage) contribute to the divergent results.
Our clinical experience has shown that the use of
low-dose GnRH-a can effectively prevent a spontaneous
LH surge and achieve similar pregnancy rates as the
standard dose. Furthermore, the decreased costs of the
lower GnRH-a dosage may overcome the cost of
increased gonadotropin use. In fact, the total costs of
gonadotropin plus GnRH-a were NT$25,600 ± 4,913
and NT$28,312 ± 5,027 in groups 1 and 2, respectively,
and these were economically favorable.
In summary, the low-dose GnRH-a down-regulation
protocol can be considered an alternative to the
standard-dose protocol. However, more studies are
needed to further evaluate the mechanisms of GnRH-a
dosage in ovarian hyperstimulation before we can
find the optimal GnRH-a dosage for ovarian hyperstim-
ulation in clinical IVF.
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